Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ezaz, Ghideon, Long, Jessica B., Gross, Cary P., Chen, Jersey
Формат: Artigo
Язык:Inglês
Опубликовано: Blackwell Publishing Ltd 2014
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959671/
https://ncbi.nlm.nih.gov/pubmed/24584736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000472
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы